Waldenstrom Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenstrom Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-11-28Clinical Trial Update: Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia [Phase 1, Phase 2]
This update reports on a phase 1/2 clinical trial of lenalidomide in relapse/refractory Waldenstrom macroglobulinemia, which has completed.
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia [Phase 2]
Phase 2 trial evaluating the safety and efficacy of rituximab plus pembrolizumab in relapsed/refractory Waldenstrom macroglobulinemia has co…
-
CLINICAL_TRIALS trial_result · 2024-01-22Clinical Trial Update: Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors [EARLY_Phase 1]
Early-phase trial assessing serologic response to SHINGRIX in patients with CLL or WM treated with BTK inhibitors; completed with results po…
-
CLINICAL_TRIALS trial_result · 2023-06-23Clinical Trial Update: Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial assessing efficacy and safety of umbralisib in non-follicular indolent non-Hodgkin lymphoma has completed with results posted …
-
CLINICAL_TRIALS trial_result · 2021-05-07Clinical Trial Update: Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas [Phase 2]
Phase 2 trial evaluating lenalidomide with low-dose dexamethasone and rituximab in rituximab-resistant, non-aggressive B-cell lymphomas; com…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies [Phase 2]
Phase 2 clinical trial assessing donor atorvastatin to prevent severe acute GVHD after nonmyeloablative peripheral blood stem cell transplan…
-
CLINICAL_TRIALS trial_result · 2017-05-04Clinical Trial Update: Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating pentostatin and lymphocyte infusion to prevent graft rejection after donor stem cell transplantation—compl…
-
CLINICAL_TRIALS trial_result · 2016-04-08Clinical Trial Update: Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia [Phase 2]
Phase 2 trial evaluating the combination of bortezomib, dexamethasone, and rituximab in Waldenstrom's macroglobulinemia has completed, with …
-
CLINICAL_TRIALS trial_result · 2015-06-08Clinical Trial Update: Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial completion evaluating a fusion protein cytokine therapy after Rituximab in patients with B-cell non-Hodgkin lymphomas.
-
CLINICAL_TRIALS trial_result · 2013-01-18Clinical Trial Update: Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia [Phase 2]
Phase 2 trial evaluates the efficacy of bortezomib (Velcade) in patients with advanced Waldenstrom macroglobulinemia.
-
CLINICAL_TRIALS trial_result · 2012-09-18Clinical Trial Update: Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating pralatrexate and gemcitabine with B12 and folic acid in relapsed/refractory lymphoproliferative malignan…